Education
About Us
Working with TipRanks
Follow Us
Chemours Company (CC)
NYSE:CC
Top Page
Chemours Company
(NYSE:CC)
Select Model
Select Model
Rating:49Neutral
Price Target:
$12.00
▼(-7.34% Downside)
Chemours Company faces significant financial challenges with declining revenue and profitability, which heavily impacts its overall score. While there are positive developments in the TSS segment and strategic financial moves to improve liquidity, the technical indicators and valuation metrics suggest caution. The company's ability to navigate macroeconomic challenges and operational inefficiencies will be crucial for future performance.
Positive Factors
Opteon Sales Growth
The strong growth in Opteon sales demonstrates Chemours' successful penetration in the refrigerants market, which is likely to sustain revenue growth and improve profitability in the long term.
Loan Maturity Extension
Extending the loan maturity provides Chemours with increased financial flexibility and stability, allowing more time for strategic investments and debt management, which supports long-term financial health.
Technical Qualification in TSS
This technical qualification enhances Chemours' position in the liquid cooling market, potentially driving future growth and innovation in the TSS segment.
Negative Factors
Declining Revenue
Declining revenue indicates challenges in market demand and competitiveness, which can hinder long-term growth and profitability if not addressed.
High Leverage
High leverage can strain financial resources and limit strategic flexibility, potentially impacting Chemours' ability to invest in growth opportunities.
Weak Cash Flow Generation
Weak cash flow generation limits Chemours' ability to fund operations and invest in growth, posing a risk to long-term financial stability.
Chemours Company (CC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.94B
Dividend Yield3.96%
Average Volume (3M)2.83M
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue Growth2.12%
EPS Growth-579.74%
CountryUS
Employees6,000
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.20
Shares Outstanding149,891,950
10 Day Avg. Volume2,411,459
30 Day Avg. Volume2,825,431
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.18
Price to Sales (P/S)0.44
P/FCF Ratio-2.54
Enterprise Value/Market Cap3.19
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit6.06
Enterprise Value/Ebitda9.41
Forecast
1Y Price Target
$16.25Price Target Upside25.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chemours Company Business Overview & Revenue Model
Company DescriptionChemours Company (CC) is a global leader in the chemical industry, specializing in the production of titanium dioxide, fluoroproducts, and chemical solutions. The company operates in three main segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions, offering a wide range of products that serve various industries including automotive, construction, electronics, and consumer products. Chemours is dedicated to sustainable practices and innovation, providing high-performance materials and solutions that meet the evolving needs of its customers.
How the Company Makes MoneyChemours generates revenue primarily through the sale of its core products across its three business segments. The Titanium Technologies segment is a significant source of income, producing titanium dioxide, which is widely used as a pigment in paints, coatings, and plastics. The Fluoroproducts segment includes a variety of fluorinated products that are essential in refrigeration, air conditioning, and other industrial applications. The Chemical Solutions segment provides custom and specialty chemicals for various applications. Additionally, Chemours has established key partnerships and collaborations within the industry that enhance its market reach and product offerings. The company also focuses on operational efficiency and cost management to bolster its profit margins, contributing to its overall financial performance.
Chemours Company Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 05, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong growth in the TSS segment, particularly with Opteon sales and strategic advancements in liquid cooling products. However, these positives were countered by significant challenges in the TT segment, including macroeconomic weakness, destocking, and operational disruptions. While cost structure improvements were noted, the lowlights reflect substantial negative trends in key markets.Q3-2025 Updates
Positive Updates
Record Opteon Sales Growth
Opteon sales maintained double-digit growth of 80% compared to the prior year quarter, marking a third quarter record. Opteon Refrigerants now account for 80% of total refrigerant sales, an increase from 58% in the previous year.
Successful Technical Qualification in TSS
The TSS segment achieved successful technical qualification of the two-phase immersion cooling fluid by Samsung Electronics, enhancing the commercialization of liquid cooling products.
Operational Recovery in APM
APM business saw solid top-line performance with the resumption of normal operations at Washington Works following external utility disruptions. The segment made strategic progress by completing the shutdown of the SPS Capstone product line.
Cost Structure Improvements
Chemours made progress against underlying cost structure, with cost-out efforts contributing to improved financial performance.
Negative Updates
TT Segment Underperformance
The TT segment delivered results below expectations due to sustained macroeconomic weakness in the global TiO2 market and near-term destocking trends in key Western markets.
Impact of Operational Disruptions
Chemours faced onetime operational disruptions earlier in the year, contributing to approximately $100 million in negative impacts, which affected overall financial performance.
Decreased Production in TT
Anticipated decrease in TT production volumes due to weak market demand, resulting in a $25 million cost impact to adjusted EBITDA in the fourth quarter.
Challenges in Global TiO2 Market
Weak demand conditions and increased inventory from Western producers added pressure to the TiO2 market, impacting Chemours' sales and pricing strategies.
Company Guidance
During the third quarter 2025 earnings call, Chemours exceeded its adjusted EBITDA expectations, driven by strong sales of Opteon Refrigerants, which grew 80% year-over-year. The TSS segment reported a 35% adjusted EBITDA margin, with Opteon now accounting for 80% of total refrigerant sales, up from 58% the prior year. However, the TT segment faced challenges with a sequential net sales decline expected in the high single digits to low teens percentage range due to destocking and macroeconomic weakness. For Q4, consolidated net sales are projected to decrease by 10% to 15% sequentially, with adjusted EBITDA ranging from $130 million to $160 million. Full year 2025 sales are anticipated between $5.7 billion and $5.8 billion, with adjusted EBITDA between $745 million and $770 million. Looking ahead, Chemours expects continued growth, with Opteon maintaining double-digit growth and additional benefits from cost-out efforts and capacity expansions.Chemours Company Financial Statement Overview
Summary
Chemours Company is facing financial challenges with declining revenue and profitability, high leverage, and weak cash flow generation. The income statement shows a declining trend in revenue with a negative revenue growth rate of -10.2% in TTM. The balance sheet reveals a high debt-to-equity ratio of 0.86, and cash flow analysis indicates a substantial decline in free cash flow growth at -120% in TTM.Income Statement
The income statement shows a declining trend in revenue with a negative revenue growth rate of -10.2% in TTM. Gross profit margin has decreased from 21.67% in 2023 to 17.37% in TTM, indicating reduced profitability. The net profit margin is negative at -5.67% in TTM, reflecting a net loss. EBIT and EBITDA margins have also declined, highlighting operational challenges.45
Neutral
Balance Sheet
The balance sheet reveals a high debt-to-equity ratio of 0.86 in TTM, which is an improvement from previous years but still indicates significant leverage. Return on equity is negative at -77.53% in TTM, due to net losses, which is concerning. The equity ratio stands at 3.94%, showing a low proportion of equity financing.50
Neutral
Cash Flow
Cash flow analysis indicates a substantial decline in free cash flow growth at -120% in TTM. The operating cash flow to net income ratio is 0.14, suggesting weak cash generation relative to net income. The free cash flow to net income ratio is low at 2.64%, reflecting limited free cash flow relative to net losses.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.87B | 5.78B | 6.08B | 6.83B | 6.34B | 4.97B |
| Gross Profit | 1.02B | 1.15B | 1.31B | 1.62B | 1.38B | 1.07B |
| EBITDA | 658.00M | 692.00M | 197.00M | 1.20B | 1.18B | 767.00M |
| Net Income | -333.00M | 86.00M | -238.00M | 578.00M | 608.00M | 219.00M |
Balance Sheet | ||||||
| Total Assets | 7.57B | 7.51B | 8.25B | 7.64B | 7.55B | 7.08B |
| Cash, Cash Equivalents and Short-Term Investments | 613.00M | 713.00M | 1.20B | 1.10B | 1.45B | 1.10B |
| Total Debt | 4.42B | 4.36B | 4.30B | 3.88B | 3.99B | 4.28B |
| Total Liabilities | 7.27B | 6.91B | 7.51B | 6.53B | 6.47B | 6.27B |
| Stockholders Equity | 298.00M | 604.00M | 737.00M | 1.11B | 1.08B | 813.00M |
Cash Flow | ||||||
| Free Cash Flow | -12.00M | -993.00M | 186.00M | 448.00M | 537.00M | 540.00M |
| Operating Cash Flow | 265.00M | -633.00M | 556.00M | 755.00M | 814.00M | 807.00M |
| Investing Cash Flow | -270.00M | -353.00M | -229.00M | -284.00M | 220.00M | -234.00M |
| Financing Cash Flow | -4.00M | -36.00M | 172.00M | -686.00M | -554.00M | -449.00M |
Chemours Company Technical Analysis
Positive
12.95
Price Trends
12.89
Positive
13.83
Negative
12.93
Positive
Market Momentum
0.05
Negative
54.28
Neutral
73.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CC, the sentiment is Positive. The current price of 12.95 is above the 20-day moving average (MA) of 12.15, above the 50-day MA of 12.89, and above the 200-day MA of 12.93, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 54.28 is Neutral, neither overbought nor oversold. The STOCH value of 73.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CC.
Chemours Company Risk Analysis
Chemours Company disclosed 39 risk factors in its most recent earnings report. Chemours Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chemours Company Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | $2.71B | -3.24 | -34.45% | 2.79% | -13.67% | -608.89% | |
58 Neutral | $2.41B | -272.85 | -0.64% | 1.41% | 0.08% | -107.33% | |
58 Neutral | $2.12B | -32.20 | -38.91% | ― | -13.39% | 88.25% | |
54 Neutral | $1.94B | -1,329.76 | -0.09% | 2.19% | -4.49% | -100.80% | |
52 Neutral | $2.53B | 47.82 | 2.67% | 3.61% | 4.68% | -62.80% | |
49 Neutral | $1.94B | -5.84 | -69.74% | 3.96% | 2.12% | -579.74% |
* Basic Materials Sector Average
CC
Chemours Company
12.95
-5.12
-28.33%
ASH
Ashland
59.15
-12.42
-17.35%
IOSP
Innospec
78.19
-35.30
-31.10%
OLN
Olin
22.18
-11.93
-34.98%
KWR
Quaker Chemical
138.99
-9.62
-6.47%
NGVT
Ingevity
58.87
14.16
31.67%
Chemours Company Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Chemours Approves New Executive Severance Policy
Neutral
Oct 31, 2025
On October 28, 2025, The Chemours Company‘s Board of Directors approved a new Executive Severance Policy to provide payments and benefits to executive officers and certain employees upon specified terminations of employment. This policy aims to offer financial security to executives in cases of involuntary termination without cause or resignation for good reason, potentially impacting the company’s operational stability and employee retention strategies.
Private Placements and FinancingBusiness Operations and Strategy
Chemours Extends $1.05 Billion Loan Maturity
Positive
Oct 16, 2025
On October 15, 2025, Chemours Company amended its credit agreement to extend the maturity date of a $1.05 billion term loan facility to October 15, 2032, and adjusted the applicable margin rates. This move is likely to impact the company’s financial stability positively by providing more time for repayment and potentially reducing interest expenses. Additionally, on October 13, 2025, Chemours’ subsidiaries entered into a Receivables Purchase Agreement with BNP Paribas Factor GmbH, allowing the sale of receivables up to €180 million. This agreement could enhance liquidity for Chemours by converting receivables into immediate cash, thus supporting its operational cash flow.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.